Calcium-phosphate homeostasis in secondary progressive multiple sclerosis patients during mitoxantrone therapy.
Martyna LisNatalia NiedzielaMaria Magdalena NowakKatarzyna Kubicka-BączykMonika Adamczyk-SowaPublished in: Neurological research (2021)
Deficiency of VitD was observed at the baseline in most SPMS patients eligible for MTX therapy. Due to adverse reactions to MTX treatment, this therapy requires patient compliance, cautious drug administration and monitoring during the therapy.
Keyphrases
- multiple sclerosis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- emergency department
- patient reported outcomes
- case report
- white matter
- replacement therapy
- drug administration
- mesenchymal stem cells
- bone marrow
- cell therapy
- smoking cessation